TAKEDA PHARMACEUTICAL CO LTD
TAKNext catalyst
TAK-360
Idiopathic Hypersomnia
Get an email about TAK's next catalysts
Track TAKEDA PHARMACEUTICAL CO (TAK) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 16 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
17 upcoming, 1 past
TAK-360 Phase 2 Est. Readout
Estimated primary completion for TAK-360 trial (NCT06812078) in Idiopathic Hypersomnia. Topline data typically follows completion by weeks to months.
SourceIxazomib Phase 2 Est. Readout
Estimated primary completion for Ixazomib trial (NCT04009109) in Myeloma, Multiple. Topline data typically follows completion by weeks to months.
SourceFOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Phase 2 Est. Readout
Estimated primary completion for FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) trial (NCT07011576) in Colon Cancer. Topline data typically follows completion by weeks to months.
SourceMaribavir Phase 3 Est. Readout
Primary completion for Maribavir trial (NCT05319353) in Cytomegalovirus (CMV)
SourceZasocitinib (Dose A) Phase 2 Est. Readout
Primary completion for Zasocitinib (Dose A) trial (NCT07244263) in Hidradenitis Suppurativa
SourceTeduglutide Phase 3 Est. Readout
Primary completion for Teduglutide trial (NCT06973304) in Short Bowel Syndrome
SourceTAK-279 Phase 2 Est. Readout
Estimated primary completion for TAK-279 trial (NCT06233461) in Crohn's Disease. Topline data typically follows completion by weeks to months.
SourceC1 Esterase Inhibitor Injection Phase 2 Est. Readout
Estimated primary completion for C1 Esterase Inhibitor Injection trial (NCT06359782) in Subarachnoid Hemorrhage, Aneurysmal. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect".
WebsiteTeduglutide
Short Bowel Syndrome
IGSC
Primary Immunodeficiency Disease
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
Ramelteon
Sleep Initiation and Maintenance Disorders
TDV
Dengue Fever
Dexlansoprazole MR
Gastroesophageal Reflux Disease
Ixazomib
Multiple Myeloma
AMG 479
Adenocarcinoma of the Pancreas
SYR-472
Diabetes Mellitus
TAK-583
Neuralgia, Postherpetic
Darvadstrocel
Crohn's Disease
Omega-3-acid ethyl esters 90 (TAK-085)
Hypertriglyceridemia
TAK-536CCB
Grade I or II Essential Hypertension
Lansoprazole and naproxen and aspirin
Osteoarthritis
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Colorectal Cancer
Pioglitazone and Metformin
Diabetes Mellitus
Idursulfase-IT
Hunter Syndrome
Lanadelumab
Angioedema
Azilsartan medoxomil and hydrochlorothiazide
Essential Hypertension
Olmesartan medoxomil and hydrochlorothiazide
Essential Hypertension
Alogliptin and insulin
Diabetes Mellitus
Rabeprazole sodium
Healthy Volunteers
Trelagliptin
Type 2 Diabetes Mellitus
Glimepiride
Diabetes Mellitus, Type 2
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
Multiple Myeloma
Parathyroid hormone
Disruption or Dehiscence of Closure of Sternum or Sternotomy
Amoxicillin
H. Pylori Infection
Lubiprostone Capsule, Fasted
Healthy Volunteers
Epoetin alfa or Epoetin beta
Chronic Renal Failure
SHP615
Nervous System Diseases
Magnesium Pantoprazole
GERD
Olmesartan medoxomil-hydrochlorothiazide
Essential Hypertension
PEGylated Recombinant Factor VIII
Hemophilia A
Vortioxetine tablets
Major Depressive Disorder
ciclesonide (XRP1526)
Respiratory Tract Diseases
Leuprorelin
Prostatic Neoplasms
Resatorvid
Sepsis
Alogliptin and glyburide
Diabetes Mellitus
IGI
Multiple Myeloma
SYR-322-MET
Clinical Pharmacology
Vonicog Alfa
Von Willebrand Disease (VWD)
TAK-559
Diabetes Mellitus
Mezagitamab
Immune Thrombocytopenic Purpura (ITP)
Active Comparator
Psoriatic Arthritis
Alogliptin and voglibose
Type 2 Diabetes Mellitus
Dexlansoprazole MR QD
Gastroesophageal Reflux
Deucravacitinib
Plaque Psoriasis
Epoetin
Chronic Kidney Disease
von Willebrand factor (Recombinant)
Von Willebrand Disease
rVWF
Von Willebrand Disease (VWD)
Azilsartan medoxomil and olmesartan
Hypertension
Lu AA21004
Major Depressive Disorder
TAK-536TCH tablet
Essential Hypertension
YF-17D
Dengue
Ixazomib Citrate
Multiple Myeloma
Lapaquistat acetate and simvastatin
Hypercholesterolemia
Upadacitinib
Crohn's Disease
MOVIPREP
Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.
Velaglucerase Alfa
Gaucher Disease
Lapaquistat acetate and rosuvastatin
Hypercholesterolemia
TAK-928
IO-resistant sqNSCLC
NE-58095 IR
Involutional Osteoporosis
Relugolix
Uterine Fibroids
REPLAGAL
Fabry Disease
TVP-1012
Parkinson's Disease
Actovegin
Peripheral Arterial Diseases
TachoSil®
Hemorrhage
Febuxostat
Gout
Epoetin Alfa
Myelodysplastic Syndrome
Apremilast
Plaque Psoriasis
TAK-330
Coagulation Disorder
Allopurinol
Gout
Voglibose
Type 2 Diabetes Mellitus
TAK-771
Primary Immunodeficiency Diseases (PID)
Surgicel® Original
Bleeding
TAP-144-SR(6M)
Prostate Cancer
Fasiglifam
Diabetes Mellitus, Type 2
Alogliptin Benzoate
Diabetes Mellitus, Type 2
Febuxostat IR
Gout
TAK-360
Idiopathic Hypersomnia
Metformin HCl
Diabetes Mellitus
TAK-667
Hereditary Angioedema
Leuprorelin SR
Prostatic Neoplasms, Locally Advanced
VONVENDI
Von Willebrand Disease (VWD)
Azilsartan medoxomil with or without add-on chlorthalidone
Hypertension
Eicosapentaenoic acid-ethyl (EPA-E)
Hypertriglyceridemia
Augmented autologous stem cell transplant (ASCT-aug)
Multiple Myeloma
ITD consolidation and ixazomib maintenance vs. No further therapy
Multiple Myeloma
Antihemophilic Factor (Recombinant)
Von Willebrand Disease
rozerem
Insomnia
Alogliptin and Metformin Fixed-Dose Combination (FDC)
Diabetes Mellitus
ITI
Hemophilia A
Febuxostat XR
Gout
Pioglitazone and Glimepiride
Diabetes Mellitus
trifluridine/tipiracil
Metastatic Oesogastric Adenocarcinoma
High Dose Colchicine (total dose)
Gout
Low-dose rtPA
Ischemic Stroke
FEIBA
Hemophilia A
MHOS/SHP615
Nervous System Diseases
NE-58095 DR
Involutional Osteoporosis
ADVATE
Von Willebrand Disease (VWD)
rFVIII
Von Willebrand Disease (VWD)
HYQVIA
Primary Immunodeficiency Diseases (PID)
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications
Hypertension
Lapaquistat acetate and atorvastatin
Hypercholesterolemia
Glyburide
Diabetes Mellitus
Lapaquistat acetate and additional lipid-lowering therapy
Hypercholesterolemia
Azilsartan medoxomil with or without add-on hydrochlorothiazide
Hypertension
HCTZ
Essential Hypertension
TAK-536CCB tablet
Essential Hypertension
Colchicine
Atrial Fibrillation
Vedolizumab
Colitis, Ulcerative
TAK-861
Narcolepsy Type 1
Azilsartan medoxomil and chlorthalidone
Essential Hypertension
Glipizide
Diabetes Mellitus
Vortioxetine
Major Depressive Disorder
TAK-881
Primary Immunodeficiency Diseases (PID)
TAK-536
Hypertension
Alogliptin and metformin
Type 2 Diabetes Mellitus
Parathyroid Hormone (PTH)
Osteoporosis
Lapaquistat Acetate
Dyslipidemia
Alogliptin and glimepiride
Type 2 Diabetes Mellitus
Rapid-acting insulin secretagogue
Diabetes Mellitus
Brentuximab Vedotin
Lymphoma
Candesartan
Heart Failure
Glimepiride and Metformin
Diabetes Mellitus
Magnesium Esomeprazole
GERD
Elaprase
Hunter Syndrome
IGIV GAMUNEX®-C
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
rFVIIa
Hemophilia A
IGIV GAMMAGARD LIQUID/KIOVIG
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Venticute
Pneumonia
Alogliptin
Diabetes Mellitus, Type 2
Azilsartan medoxomil - chlorthalidone
Essential Hypertension
Azilsartan medoxomil
Essential Hypertension
Zasocitinib
Psoriatic Arthritis
TAK-019
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
TAK-438
Gastric Ulcers
Chlorthalidone
Hypertension
Adynovate
Hemophilia A
Bismuth-Containing Quadruple Therapy
Duodenal Ulcer
Azilsartan Medoxomil and amlodipine
Hypertension
Soticlestat
Dravet Syndrome (DS)
Lansoprazole
Esophagitis, Reflux
Vedolizumab IV
Moderately to Severely Active Ulcerative Colitis
Rosiglitazone
Diabetes Mellitus
Candesartan cilexetil
Essential Hypertension
Low Dose Colchicine (total dose)
Gout
TAK-536CCB + Hydrochlorothiazide
Grade I or II Essential Hypertension
TAK-279
Plaque Psoriasis
Lapaquistat acetate and ezetimibe
Hypercholesterolemia
9vHPV Vaccine
Dengue Fever
Vonoprazan
Gastroesophageal Reflux
Zopiclone
Balance
Elritercept
Myelodysplastic Syndromes
Dexlansoprazole
Gastroesophageal Reflux Disease
Ramipril
Hypertension
Valsartan
Hypertension
TAK-672
Acquired Hemophilia A
Vedolizumab SC
Ulcerative Colitis
Lubiprostone
Constipation
Gefarnate
Stomach Ulcer
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
Intranasal Fentanyl Spray (INFS)
Break Through Pain
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Dengue Fever
Metformin hydrochloride
Type 2 Diabetes Mellitus
Azilsartan
Hypertension
Lansoprazole microgranules suspension
Gastroesophageal Reflux Disease
Peginesatide
Anemia
Concomitant Antibiotic Therapy
Pouchitis
TAK-743
Hereditary Angioedema
Cyclobenzaprine HCl
Neck Pain
TAK-625
Alagille Syndrome (ALGS)
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
TAK-875
Diabetes Mellitus
TAK-003
Dengue Fever
TAK-816
Healthy Volunteers
Brigatinib
ALK-positive Advanced NSCLC
Cyproterone acetate
Adenocarcinoma, Prostate
Escitalopram
Treatment Outcome
Maribavir
Cytomegalovirus (CMV)
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
TAK-816+ DPT-TAKEDA
Immunization
Lapaquistat acetate and lipid-lowering therapy
Type 2 Diabetes
Alectinib
ALK+ Advanced NSCLC
HAV Vaccine
Healthy Volunteers
B-MAD chemotherapy
Extranodal NK/T-cell Lymphoma
TAK-062
Celiac Disease
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
Dengue Fever
Leuprorelin acetate
Endometriosis
TAK-853
Ovarian Cancer
FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Colon Cancer
Pioglitazone and insulin
Diabetes Mellitus
Namilumab
Rheumatoid Arthritis
Ramelteon and doxepin
Sleep Initiation and Maintenance Disorders
Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
TAK-788
Carcinoma, Non-Small-Cell Lung
Tak-228 & Tak-117
Triple Negative Breast Cancer
TIMP-GLIA
Celiac Disease
Subcutaneous injection of TAK-850
Influenza Infection
Chemotherapy Agents
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
TAK-128
Diabetic Neuropathies
Zasocitinib (Dose A)
Hidradenitis Suppurativa
Norwalk VLP vaccine
Acute Gastroenteritis
Pioglitazone and ramipril
Inflammation
TAK228
Ovarian Cancer
TAK-385
Uterine Fibroids
Immune Globulin Infusion (Human)
Hematologic Malignancies
NoV Vaccine
Healthy Volunteers
TAK-981
Advanced or Metastatic Solid Tumors
Rusfertide
Polycythemia Vera
GI.1/GII.4 (15/50)
Norovirus
TAK-101
Celiac Disease
Dazostinag
Solid Neoplasms
TAK-954
Postoperative Gastrointestinal Dysfunction
TAK-079
Primary Immune Thrombocytopenia
MCC-135
Congestive Heart Failure
Methotrexate (IT)
ALL, Childhood
TAK-063
Schizophrenia
Ondansetron
Nausea
TAK-662
Congenital Protein C Deficiency
TAK-919
Coronavirus Disease (COVID-19)
TAK-850
Influenza Infection
GDX012
Leukemia
Alisertib
Acute Myeloid Leukemia
Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
ALL, Childhood
GI.1/GII.4 (50/50)
Norovirus
TAK-188
Advanced or Metastatic Solid Tumors
Levothyroxine sodium new formulation
Hypothyroidism
TD-8954
Enteral Feeding Intolerance
SHP655
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
GI.1/GII.4 (50/150)
Norovirus
TAK-783 and methotrexate
Arthritis, Rheumatoid
Norovirus Bivalent Vaccine
Prevention From Norovirus Infection
Panitumumab + TAS-102
Colorectal Cancer
TAK-935
Developmental and/or Epileptic Encephalopathies
Ramelteon and gabapentin
Sleep Initiation and Maintenance Disorders
Pevonedistat
Acute Myeloid Leukemia (AML)
TAK-226
Myelodysplastic Syndromes
TAK-505
Malignant Solid Tumors
Norwalk virus
Acute Gastroenteritis
C1 Esterase Inhibitor Injection
Subarachnoid Hemorrhage, Aneurysmal
Adcetris-Levact
Clinical Efficacy
TAK-071
Parkinson Disease
Leuprorelin (GF)
Uterine Fibroids
Olmesartan
Hypertension
AMG 706
Advanced Gastrointestinal Stromal Tumor
Fruquintinib Combined With Chemotherapy
Metastatic Colorectal Cancer (CRC)
BAX 888
Hemophilia A
TDV Liquid Formulation 2
Dengue Fever
Intramuscular injection of TAK-850
Influenza Infection
Ilaprazole
Esophagitis
TAK-715 and methotrexate
Arthritis, Rheumatoid
Niraparib
Ovarian Cancer
TDV Liquid Formulation 1
Dengue Fever
Lapaquistat acetate and fenofibrate
Hyperlipidemias
Melphalan
Multiple Myeloma
TAK-875 and Sitagliptin
Diabetes Mellitus, Type 2
Anti-CD19 CAR T Cells Preparation
Hematologic Malignancies
Pioglitazone and azilsartan
Diabetes Mellitus
HGT-1110
Metachromatic Leukodystrophy (MLD)
Asparaginase
ALL, Childhood
Luvadaxistat
Schizophrenia
Leuprorelin (GC)
Uterine Fibroids
Pioglitazone and atorvastatin
Cardiovascular Diseases
Cisplatin & Nab Paclitaxel
Triple Negative Breast Cancer
SHP611
Metachromatic Leukodystrophy (MLD)
Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Dengue Fever
Prednisone (and methylprednisolone)
Immune Checkpoint Inhibitor-Related Colitis
TAK-341
Multiple System Atrophy
Norovirus Bivalent VLP Vaccine
Norovirus Prevention
Folic/folinic acid
Rheumatoid Arthritis
TAK-272
Type 2 Diabetes Mellitus and Microalbuminuria
TDV IDT Lyophilized
Dengue Fever
Hepatitis A Vaccine
Healthy Volunteers
NoV GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
TAK-442
Acute Coronary Syndrome
TAK-007
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
GI.1/GII.4 (15/15)
Norovirus
vortioxetine (Lu AA21004)
Depressive Disorder, Major
TAK-411
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
TAK-951
Postoperative Nausea and Vomiting (PONV)
Ponatinib
Myeloid Leukemia, Chronic, Chronic Phase
NDI-034858 study drug
Moderate to Severe Plaque Psoriasis
NDI-034858
Psoriatic Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Teduglutide | Phase 3 | Short Bowel Syndrome | - | - |
IGSC | Phase 3 | Primary Immunodeficiency Disease | - | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ramelteon | Phase 3 | Sleep Initiation and Maintenance Disorders | - | - |
TDV | Phase 3 | Dengue Fever | - | - |
Dexlansoprazole MR | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Ixazomib | Phase 3 | Multiple Myeloma | - | - |
AMG 479 | Phase 3 | Adenocarcinoma of the Pancreas | - | - |
SYR-472 | Phase 3 | Diabetes Mellitus | - | - |
TAK-583 | Phase 3 | Neuralgia, Postherpetic | - | - |
Darvadstrocel | Phase 3 | Crohn's Disease | - | - |
Omega-3-acid ethyl esters 90 (TAK-085) | Phase 3 | Hypertriglyceridemia | - | - |
TAK-536CCB | Phase 3 | Grade I or II Essential Hypertension | - | - |
Lansoprazole and naproxen and aspirin | Phase 3 | Osteoarthritis | - | - |
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Phase 3 | Colorectal Cancer | - | - |
Pioglitazone and Metformin | Phase 3 | Diabetes Mellitus | - | - |
Idursulfase-IT | Phase 3 | Hunter Syndrome | - | - |
Lanadelumab | Phase 3 | Angioedema | - | - |
Azilsartan medoxomil and hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
Olmesartan medoxomil and hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
Alogliptin and insulin | Phase 3 | Diabetes Mellitus | - | - |
Rabeprazole sodium | Phase 3 | Healthy Volunteers | - | - |
Trelagliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Glimepiride | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction | Phase 3 | Multiple Myeloma | - | - |
Parathyroid hormone | Phase 3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | - | - |
Amoxicillin | Phase 3 | H. Pylori Infection | - | - |
Lubiprostone Capsule, Fasted | Phase 3 | Healthy Volunteers | - | - |
Epoetin alfa or Epoetin beta | Phase 3 | Chronic Renal Failure | - | - |
SHP615 | Phase 3 | Nervous System Diseases | - | - |
Magnesium Pantoprazole | Phase 3 | GERD | - | - |
Olmesartan medoxomil-hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
PEGylated Recombinant Factor VIII | Phase 3 | Hemophilia A | - | - |
Vortioxetine tablets | Phase 3 | Major Depressive Disorder | - | - |
ciclesonide (XRP1526) | Phase 3 | Respiratory Tract Diseases | - | - |
Leuprorelin | Phase 3 | Prostatic Neoplasms | - | - |
Resatorvid | Phase 3 | Sepsis | - | - |
Alogliptin and glyburide | Phase 3 | Diabetes Mellitus | - | - |
IGI | Phase 3 | Multiple Myeloma | - | - |
SYR-322-MET | Phase 3 | Clinical Pharmacology | - | - |
Vonicog Alfa | Phase 3 | Von Willebrand Disease (VWD) | - | - |
TAK-559 | Phase 3 | Diabetes Mellitus | - | - |
Mezagitamab | Phase 3 | Immune Thrombocytopenic Purpura (ITP) | - | - |
Active Comparator | Phase 3 | Psoriatic Arthritis | - | - |
Alogliptin and voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Dexlansoprazole MR QD | Phase 3 | Gastroesophageal Reflux | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
Epoetin | Phase 3 | Chronic Kidney Disease | - | - |
von Willebrand factor (Recombinant) | Phase 3 | Von Willebrand Disease | - | - |
rVWF | Phase 3 | Von Willebrand Disease (VWD) | - | - |
Azilsartan medoxomil and olmesartan | Phase 3 | Hypertension | - | - |
Lu AA21004 | Phase 3 | Major Depressive Disorder | - | - |
TAK-536TCH tablet | Phase 3 | Essential Hypertension | - | - |
YF-17D | Phase 3 | Dengue | - | - |
Ixazomib Citrate | Phase 3 | Multiple Myeloma | - | - |
Lapaquistat acetate and simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Upadacitinib | Phase 3 | Crohn's Disease | - | - |
MOVIPREP | Phase 3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | - | - |
Velaglucerase Alfa | Phase 3 | Gaucher Disease | - | - |
Lapaquistat acetate and rosuvastatin | Phase 3 | Hypercholesterolemia | - | - |
TAK-928 | Phase 3 | IO-resistant sqNSCLC | - | - |
NE-58095 IR | Phase 3 | Involutional Osteoporosis | - | - |
Relugolix | Phase 3 | Uterine Fibroids | - | - |
REPLAGAL | Phase 3 | Fabry Disease | - | - |
TVP-1012 | Phase 3 | Parkinson's Disease | - | - |
Actovegin | Phase 3 | Peripheral Arterial Diseases | - | - |
TachoSil® | Phase 3 | Hemorrhage | - | - |
Febuxostat | Phase 3 | Gout | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndrome | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
TAK-330 | Phase 3 | Coagulation Disorder | - | - |
Allopurinol | Phase 3 | Gout | - | - |
Voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TAK-771 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Surgicel® Original | Phase 3 | Bleeding | - | - |
TAP-144-SR(6M) | Phase 3 | Prostate Cancer | - | - |
Fasiglifam | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Alogliptin Benzoate | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Febuxostat IR | Phase 3 | Gout | - | - |
TAK-360 | Phase 3 | Idiopathic Hypersomnia | - | - |
Metformin HCl | Phase 3 | Diabetes Mellitus | - | - |
TAK-667 | Phase 3 | Hereditary Angioedema | - | - |
Leuprorelin SR | Phase 3 | Prostatic Neoplasms, Locally Advanced | - | - |
VONVENDI | Phase 3 | Von Willebrand Disease (VWD) | - | - |
Azilsartan medoxomil with or without add-on chlorthalidone | Phase 3 | Hypertension | - | - |
Eicosapentaenoic acid-ethyl (EPA-E) | Phase 3 | Hypertriglyceridemia | - | - |
Augmented autologous stem cell transplant (ASCT-aug) | Phase 3 | Multiple Myeloma | - | - |
ITD consolidation and ixazomib maintenance vs. No further therapy | Phase 3 | Multiple Myeloma | - | - |
Antihemophilic Factor (Recombinant) | Phase 3 | Von Willebrand Disease | - | - |
rozerem | Phase 3 | Insomnia | - | - |
Alogliptin and Metformin Fixed-Dose Combination (FDC) | Phase 3 | Diabetes Mellitus | - | - |
ITI | Phase 3 | Hemophilia A | - | - |
Febuxostat XR | Phase 3 | Gout | - | - |
Pioglitazone and Glimepiride | Phase 3 | Diabetes Mellitus | - | - |
trifluridine/tipiracil | Phase 3 | Metastatic Oesogastric Adenocarcinoma | - | - |
High Dose Colchicine (total dose) | Phase 3 | Gout | - | - |
Low-dose rtPA | Phase 3 | Ischemic Stroke | - | - |
FEIBA | Phase 3 | Hemophilia A | - | - |
MHOS/SHP615 | Phase 3 | Nervous System Diseases | - | - |
NE-58095 DR | Phase 3 | Involutional Osteoporosis | - | - |
ADVATE | Phase 3 | Von Willebrand Disease (VWD) | - | - |
rFVIII | Phase 3 | Von Willebrand Disease (VWD) | - | - |
HYQVIA | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications | Phase 3 | Hypertension | - | - |
Lapaquistat acetate and atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Glyburide | Phase 3 | Diabetes Mellitus | - | - |
Lapaquistat acetate and additional lipid-lowering therapy | Phase 3 | Hypercholesterolemia | - | - |
Azilsartan medoxomil with or without add-on hydrochlorothiazide | Phase 3 | Hypertension | - | - |
HCTZ | Phase 3 | Essential Hypertension | - | - |
TAK-536CCB tablet | Phase 3 | Essential Hypertension | - | - |
Colchicine | Phase 3 | Atrial Fibrillation | - | - |
Vedolizumab | Phase 3 | Colitis, Ulcerative | - | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Essential Hypertension | - | - |
Glipizide | Phase 3 | Diabetes Mellitus | - | - |
Vortioxetine | Phase 3 | Major Depressive Disorder | - | - |
TAK-881 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
TAK-536 | Phase 3 | Hypertension | - | - |
Alogliptin and metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Parathyroid Hormone (PTH) | Phase 3 | Osteoporosis | - | - |
Lapaquistat Acetate | Phase 3 | Dyslipidemia | - | - |
Alogliptin and glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Rapid-acting insulin secretagogue | Phase 3 | Diabetes Mellitus | - | - |
Brentuximab Vedotin | Phase 3 | Lymphoma | - | - |
Candesartan | Phase 3 | Heart Failure | - | - |
Glimepiride and Metformin | Phase 3 | Diabetes Mellitus | - | - |
Magnesium Esomeprazole | Phase 3 | GERD | - | - |
Elaprase | Phase 3 | Hunter Syndrome | - | - |
IGIV GAMUNEX®-C | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | - | - |
rFVIIa | Phase 3 | Hemophilia A | - | - |
IGIV GAMMAGARD LIQUID/KIOVIG | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | - | - |
Venticute | Phase 3 | Pneumonia | - | - |
Alogliptin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Azilsartan medoxomil - chlorthalidone | Phase 3 | Essential Hypertension | - | - |
Azilsartan medoxomil | Phase 3 | Essential Hypertension | - | - |
Zasocitinib | Phase 3 | Psoriatic Arthritis | - | - |
TAK-019 | Phase 3 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | - | - |
TAK-438 | Phase 3 | Gastric Ulcers | - | - |
Chlorthalidone | Phase 3 | Hypertension | - | - |
Adynovate | Phase 3 | Hemophilia A | - | - |
Bismuth-Containing Quadruple Therapy | Phase 3 | Duodenal Ulcer | - | - |
Azilsartan Medoxomil and amlodipine | Phase 3 | Hypertension | - | - |
Soticlestat | Phase 3 | Dravet Syndrome (DS) | - | - |
Lansoprazole | Phase 3 | Esophagitis, Reflux | - | - |
Vedolizumab IV | Phase 3 | Moderately to Severely Active Ulcerative Colitis | - | - |
Rosiglitazone | Phase 3 | Diabetes Mellitus | - | - |
Candesartan cilexetil | Phase 3 | Essential Hypertension | - | - |
Low Dose Colchicine (total dose) | Phase 3 | Gout | - | - |
TAK-536CCB + Hydrochlorothiazide | Phase 3 | Grade I or II Essential Hypertension | - | - |
TAK-279 | Phase 3 | Plaque Psoriasis | - | - |
Lapaquistat acetate and ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
9vHPV Vaccine | Phase 3 | Dengue Fever | - | - |
Vonoprazan | Phase 3 | Gastroesophageal Reflux | - | - |
Zopiclone | Phase 3 | Balance | - | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Ramipril | Phase 3 | Hypertension | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
TAK-672 | Phase 3 | Acquired Hemophilia A | - | - |
Vedolizumab SC | Phase 3 | Ulcerative Colitis | - | - |
Lubiprostone | Phase 3 | Constipation | - | - |
Gefarnate | Phase 3 | Stomach Ulcer | - | - |
TAK-755 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP) | - | - |
Intranasal Fentanyl Spray (INFS) | Phase 3 | Break Through Pain | - | - |
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) | Phase 3 | Dengue Fever | - | - |
Metformin hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Azilsartan | Phase 3 | Hypertension | - | - |
Lansoprazole microgranules suspension | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Peginesatide | Phase 3 | Anemia | - | - |
Concomitant Antibiotic Therapy | Phase 3 | Pouchitis | - | - |
TAK-743 | Phase 3 | Hereditary Angioedema | - | - |
Cyclobenzaprine HCl | Phase 3 | Neck Pain | - | - |
TAK-625 | Phase 3 | Alagille Syndrome (ALGS) | - | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - | - |
TAK-003 | Phase 3 | Dengue Fever | - | - |
TAK-816 | Phase 3 | Healthy Volunteers | - | - |
Brigatinib | Phase 3 | ALK-positive Advanced NSCLC | - | - |
Cyproterone acetate | Phase 3 | Adenocarcinoma, Prostate | - | - |
Escitalopram | Phase 3 | Treatment Outcome | - | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - | - |
TAK-816+ DPT-TAKEDA | Phase 3 | Immunization | - | - |
Lapaquistat acetate and lipid-lowering therapy | Phase 3 | Type 2 Diabetes | - | - |
Alectinib | Phase 3 | ALK+ Advanced NSCLC | - | - |
HAV Vaccine | Phase 3 | Healthy Volunteers | - | - |
B-MAD chemotherapy | Phase 2 | Extranodal NK/T-cell Lymphoma | - | - |
TAK-062 | Phase 2 | Celiac Disease | - | - |
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) | Phase 2 | Dengue Fever | - | - |
Leuprorelin acetate | Phase 2 | Endometriosis | - | - |
TAK-853 | Phase 2 | Ovarian Cancer | - | - |
FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Phase 2 | Colon Cancer | - | - |
Pioglitazone and insulin | Phase 2 | Diabetes Mellitus | - | - |
Namilumab | Phase 2 | Rheumatoid Arthritis | - | - |
Ramelteon and doxepin | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - | - |
TAK-788 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Tak-228 & Tak-117 | Phase 2 | Triple Negative Breast Cancer | - | - |
TIMP-GLIA | Phase 2 | Celiac Disease | - | - |
Subcutaneous injection of TAK-850 | Phase 2 | Influenza Infection | - | - |
Chemotherapy Agents | Phase 2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | - | - |
TAK-128 | Phase 2 | Diabetic Neuropathies | - | - |
Zasocitinib (Dose A) | Phase 2 | Hidradenitis Suppurativa | - | - |
Norwalk VLP vaccine | Phase 2 | Acute Gastroenteritis | - | - |
Pioglitazone and ramipril | Phase 2 | Inflammation | - | - |
TAK228 | Phase 2 | Ovarian Cancer | - | - |
TAK-385 | Phase 2 | Uterine Fibroids | - | - |
Immune Globulin Infusion (Human) | Phase 2 | Hematologic Malignancies | - | - |
NoV Vaccine | Phase 2 | Healthy Volunteers | - | - |
TAK-981 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Rusfertide | Phase 2 | Polycythemia Vera | - | - |
GI.1/GII.4 (15/50) | Phase 2 | Norovirus | - | - |
TAK-101 | Phase 2 | Celiac Disease | - | - |
Dazostinag | Phase 2 | Solid Neoplasms | - | - |
TAK-954 | Phase 2 | Postoperative Gastrointestinal Dysfunction | - | - |
TAK-079 | Phase 2 | Primary Immune Thrombocytopenia | - | - |
MCC-135 | Phase 2 | Congestive Heart Failure | - | - |
Methotrexate (IT) | Phase 2 | ALL, Childhood | - | - |
TAK-063 | Phase 2 | Schizophrenia | - | - |
Ondansetron | Phase 2 | Nausea | - | - |
TAK-662 | Phase 2 | Congenital Protein C Deficiency | - | - |
TAK-919 | Phase 2 | Coronavirus Disease (COVID-19) | - | - |
TAK-850 | Phase 2 | Influenza Infection | - | - |
GDX012 | Phase 2 | Leukemia | - | - |
Alisertib | Phase 2 | Acute Myeloid Leukemia | - | - |
Triple IT (Methotrexate, Hydrocortisone, Cytarabine) | Phase 2 | ALL, Childhood | - | - |
GI.1/GII.4 (50/50) | Phase 2 | Norovirus | - | - |
TAK-188 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Levothyroxine sodium new formulation | Phase 2 | Hypothyroidism | - | - |
TD-8954 | Phase 2 | Enteral Feeding Intolerance | - | - |
SHP655 | Phase 2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | - | - |
GI.1/GII.4 (50/150) | Phase 2 | Norovirus | - | - |
TAK-783 and methotrexate | Phase 2 | Arthritis, Rheumatoid | - | - |
Norovirus Bivalent Vaccine | Phase 2 | Prevention From Norovirus Infection | - | - |
Panitumumab + TAS-102 | Phase 2 | Colorectal Cancer | - | - |
TAK-935 | Phase 2 | Developmental and/or Epileptic Encephalopathies | - | - |
Ramelteon and gabapentin | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
Pevonedistat | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
TAK-226 | Phase 2 | Myelodysplastic Syndromes | - | - |
TAK-505 | Phase 2 | Malignant Solid Tumors | - | - |
Norwalk virus | Phase 2 | Acute Gastroenteritis | - | - |
C1 Esterase Inhibitor Injection | Phase 2 | Subarachnoid Hemorrhage, Aneurysmal | - | - |
Adcetris-Levact | Phase 2 | Clinical Efficacy | - | - |
TAK-071 | Phase 2 | Parkinson Disease | - | - |
Leuprorelin (GF) | Phase 2 | Uterine Fibroids | - | - |
Olmesartan | Phase 2 | Hypertension | - | - |
AMG 706 | Phase 2 | Advanced Gastrointestinal Stromal Tumor | - | - |
Fruquintinib Combined With Chemotherapy | Phase 2 | Metastatic Colorectal Cancer (CRC) | - | - |
BAX 888 | Phase 2 | Hemophilia A | - | - |
TDV Liquid Formulation 2 | Phase 2 | Dengue Fever | - | - |
Intramuscular injection of TAK-850 | Phase 2 | Influenza Infection | - | - |
Ilaprazole | Phase 2 | Esophagitis | - | - |
TAK-715 and methotrexate | Phase 2 | Arthritis, Rheumatoid | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
TDV Liquid Formulation 1 | Phase 2 | Dengue Fever | - | - |
Lapaquistat acetate and fenofibrate | Phase 2 | Hyperlipidemias | - | - |
Melphalan | Phase 2 | Multiple Myeloma | - | - |
TAK-875 and Sitagliptin | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Anti-CD19 CAR T Cells Preparation | Phase 2 | Hematologic Malignancies | - | - |
Pioglitazone and azilsartan | Phase 2 | Diabetes Mellitus | - | - |
HGT-1110 | Phase 2 | Metachromatic Leukodystrophy (MLD) | - | - |
Asparaginase | Phase 2 | ALL, Childhood | - | - |
Luvadaxistat | Phase 2 | Schizophrenia | - | - |
Leuprorelin (GC) | Phase 2 | Uterine Fibroids | - | - |
Pioglitazone and atorvastatin | Phase 2 | Cardiovascular Diseases | - | - |
Cisplatin & Nab Paclitaxel | Phase 2 | Triple Negative Breast Cancer | - | - |
SHP611 | Phase 2 | Metachromatic Leukodystrophy (MLD) | - | - |
Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Phase 2 | Dengue Fever | - | - |
Prednisone (and methylprednisolone) | Phase 2 | Immune Checkpoint Inhibitor-Related Colitis | - | - |
TAK-341 | Phase 2 | Multiple System Atrophy | - | - |
Norovirus Bivalent VLP Vaccine | Phase 2 | Norovirus Prevention | - | - |
Folic/folinic acid | Phase 2 | Rheumatoid Arthritis | - | - |
TAK-272 | Phase 2 | Type 2 Diabetes Mellitus and Microalbuminuria | - | - |
TDV IDT Lyophilized | Phase 2 | Dengue Fever | - | - |
Hepatitis A Vaccine | Phase 2 | Healthy Volunteers | - | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - | - |
TAK-442 | Phase 2 | Acute Coronary Syndrome | - | - |
TAK-007 | Phase 2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | - | - |
GI.1/GII.4 (15/15) | Phase 2 | Norovirus | - | - |
vortioxetine (Lu AA21004) | Phase 2 | Depressive Disorder, Major | - | - |
TAK-411 | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
TAK-951 | Phase 2 | Postoperative Nausea and Vomiting (PONV) | - | - |
Ponatinib | Phase 2 | Myeloid Leukemia, Chronic, Chronic Phase | - | - |
NDI-034858 study drug | Phase 2 | Moderate to Severe Plaque Psoriasis | - | - |
NDI-034858 | Phase 2 | Psoriatic Arthritis | - | - |
psoriasis
3 drugs in this indication
narcolepsy
1 drug in this indication
sleep disorder
1 drug in this indication
Advanced colorectal cancer
1 drug in this indication
Narcolepsy Type 1
1 drug in this indication
Adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and for on-demand treatment and control of bleeding episodes
1 drug in this indication
polycythemia vera
1 drug in this indication
Fabry Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?→
CatalystAlert tracks 285 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TAK) pipeline across Phase 3, Phase 2. Its lead program is Ixazomib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?→
TAKEDA PHARMACEUTICAL CO LTD's (TAK) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TAK biotech catalysts?→
Add TAK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
